The route to personalized medicine in bladder cancer: where do we stand?

被引：12
作者：
Massari, Francesco [1 ]
Ciccarese, Chiara [1 ]
Santoni, Matteo [2 ]
Brunelli, Matteo [3 ]
Conti, Alessandro [4 ]
Modena, Alessandra [1 ]
Montironi, Rodolfo
Santini, Daniele [6 ]
Cheng, Liang [7 ]
Martignoni, Guido [3 ,5 ]
Cascinu, Stefano [2 ]
Tortora, Giampaolo [1 ]
机构：
[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, I-37100 Verona, Italy
[2] Polytech Univ Marche Reg, AOU Osped Riuniti, Med Oncol, Ancona, Italy
[3] Univ Verona, Dept Pathol & Diagnost, I-37100 Verona, Italy
[4] Polytech Univ Marche Reg, Dept Clin & Specialist Sci Urol, Ancona, Italy
[5] Polytech Univ Marche Reg, AOU Osped Riuniti, Sch Med, Sect Pathol Anat, Ancona, Italy
[6] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy
[7] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA
来源：
TARGETED ONCOLOGY | 2015年 / 10卷 / 03期
关键词：
Target agents; Bladder cancer; Novel agents; Personalized medicine; ENDOTHELIAL GROWTH-FACTOR; TRANSITIONAL-CELL CARCINOMA; METASTATIC UROTHELIAL CARCINOMA; FGFR3 MUTATION STATUS; URINARY-BLADDER; GENE AMPLIFICATION; FACTOR RECEPTOR; PHASE-II; STEM-CELLS; MESENCHYMAL TRANSITION;
D O I：
10.1007/s11523-015-0357-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent advances in molecular biology and drug design have described novel targets in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, PD-1, cyclooxygenase 2 (COX-2), Aurora kinase A, and miRNA are just examples of these opening frontiers. In addition, epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs) are promising candidates for future therapeutic approaches. Novel agents, combination, and sequences are emerging from the 747 clinical studies presently in course in bladder cancer to optimize patient outcomes. This report describes the emerging targets and provides an update on ongoing phase I, II, and III trials and preliminary results on targeted agents, used alone, in sequences, or in combination for patients with bladder cancer.
引用
收藏
页码：325 / 336
页数：12
相关论文
共 119 条
  • [1] miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy
    Adam, Liana
    Zhong, Meng
    Choi, Woonyoung
    Qi, Wei
    Nicoloso, Milena
    Arora, Ameeta
    Calin, George
    Wang, Hua
    Siefker-Radtke, Arlene
    McConkey, David
    Bar-Eli, Menashe
    Dinney, Colin
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (16) : 5060 - 5072
  • [2] AIOM - AIRTUM, 2013, NUM CANCR IT 2013, P15
  • [3] Somatic mutation of PTEN in bladder carcinoma
    Aveyard, JS
    Skilleter, A
    Habuchi, T
    Knowles, MA
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) : 904 - 908
  • [4] Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors
    Baumgart, Egbert
    Cohen, Michael S.
    Neto, Brasil Silva
    Jacobs, Micah A.
    Wotkowicz, Chad
    Rieger-Christ, Kimberly M.
    Biolo, Andreia
    Zeheb, Ron
    Loda, Massimo
    Libertino, John A.
    Summerhayes, Ian C.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (06) : 1685 - 1694
  • [5] The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro
    Becker, Marie N.
    Wu, Kevin J.
    Marlow, Laura A.
    Kreinest, Pamela A.
    vonRoemeling, Christina A.
    Copland, John A.
    Williams, Christopher R.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (03) : 317 - 326
  • [6] The FGF family: biology, pathophysiology and therapy
    Beenken, Andrew
    Mohammadi, Moosa
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) : 235 - 253
  • [7] Novel approaches with targeted therapies in bladder cancer - Therapy of bladder cancer by blockade of the epidermal growth factor receptor family
    Bellmunt, J
    Hussain, M
    Dinney, CP
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 46 : S85 - S104
  • [8] New drugs and new approaches in metastatic bladder cancer
    Bellmunt, J
    de Wit, R
    Albiol, S
    Tabernero, J
    Albanell, J
    Baselga, J
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 47 (02) : 195 - 206
  • [9] Molecular targets on the horizon for kidney and urothelial cancer
    Bellmunt, Joaquim
    Teh, Bin T.
    Tortora, Giampaolo
    Rosenberg, Jonathan E.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (10) : 557 - 570
  • [10] Beuzeboc P, 2007, J CLIN ONCOL, V25
12345678910